Chromogenic substrates for activated partial thromboplastin time testing

Are they worth using?

Research output: Contribution to journalArticle

Abstract

In hemostasis testing the development of chromogenic substrates provides an alternative to the traditional methods based on the detection of forming clots. The new technology has often replaced the clotting tests, especially in the area of single clotting factor and inhibitor assay, less frequently for global screening tests. We report studies of the validity and clinical application of two reagents for activated partial thromboplastin time (APTT) testing with chromogenic substrates in comparison with the conventional clotting method. Congenital deficiencies of the intrinsic coagulation pathway, other than hypo- and dysfibrinogenemia detected by chromogenic APTT, agreed with those detected by the clotting APTT. The results with the two methods for plasma under heparin treatment suggest a lesser responsiveness of the chromogenic methods to heparinization. The chromogenic methods demonstrated the presence of the lupus anticoagulant in the majority of tested samples of known lupus subjects, but with a lower responsiveness than the clotting method. In conclusion, we found chromogenic APTT suitable for hemostasis testing because it generally gives the same information as the conventional clotting method with the exception of heparin monitoring and lupus anticoagulant detection, where an improved sensitivity would be desirable.

Original languageEnglish
Pages (from-to)355-358
Number of pages4
JournalLa Ricerca in Clinica e in Laboratorio
Volume19
Issue number1
DOIs
Publication statusPublished - Dec 1989

Fingerprint

Chromogenics
Chromogenic Compounds
Partial Thromboplastin Time
Thromboplastin
Lupus Coagulation Inhibitor
Testing
Heparin
Blood Coagulation Factors
Hemostasis
Coagulation
Assays
Screening
Plasmas
Monitoring
Technology

Keywords

  • Activated partial thromboplastin time
  • Chromogenic substrates
  • Hemostasis screening tests

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

@article{ae52d798e1224eb191832b36eda99687,
title = "Chromogenic substrates for activated partial thromboplastin time testing: Are they worth using?",
abstract = "In hemostasis testing the development of chromogenic substrates provides an alternative to the traditional methods based on the detection of forming clots. The new technology has often replaced the clotting tests, especially in the area of single clotting factor and inhibitor assay, less frequently for global screening tests. We report studies of the validity and clinical application of two reagents for activated partial thromboplastin time (APTT) testing with chromogenic substrates in comparison with the conventional clotting method. Congenital deficiencies of the intrinsic coagulation pathway, other than hypo- and dysfibrinogenemia detected by chromogenic APTT, agreed with those detected by the clotting APTT. The results with the two methods for plasma under heparin treatment suggest a lesser responsiveness of the chromogenic methods to heparinization. The chromogenic methods demonstrated the presence of the lupus anticoagulant in the majority of tested samples of known lupus subjects, but with a lower responsiveness than the clotting method. In conclusion, we found chromogenic APTT suitable for hemostasis testing because it generally gives the same information as the conventional clotting method with the exception of heparin monitoring and lupus anticoagulant detection, where an improved sensitivity would be desirable.",
keywords = "Activated partial thromboplastin time, Chromogenic substrates, Hemostasis screening tests",
author = "Armando Tripodi",
year = "1989",
month = "12",
doi = "10.1007/BF02871825",
language = "English",
volume = "19",
pages = "355--358",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Chromogenic substrates for activated partial thromboplastin time testing

T2 - Are they worth using?

AU - Tripodi, Armando

PY - 1989/12

Y1 - 1989/12

N2 - In hemostasis testing the development of chromogenic substrates provides an alternative to the traditional methods based on the detection of forming clots. The new technology has often replaced the clotting tests, especially in the area of single clotting factor and inhibitor assay, less frequently for global screening tests. We report studies of the validity and clinical application of two reagents for activated partial thromboplastin time (APTT) testing with chromogenic substrates in comparison with the conventional clotting method. Congenital deficiencies of the intrinsic coagulation pathway, other than hypo- and dysfibrinogenemia detected by chromogenic APTT, agreed with those detected by the clotting APTT. The results with the two methods for plasma under heparin treatment suggest a lesser responsiveness of the chromogenic methods to heparinization. The chromogenic methods demonstrated the presence of the lupus anticoagulant in the majority of tested samples of known lupus subjects, but with a lower responsiveness than the clotting method. In conclusion, we found chromogenic APTT suitable for hemostasis testing because it generally gives the same information as the conventional clotting method with the exception of heparin monitoring and lupus anticoagulant detection, where an improved sensitivity would be desirable.

AB - In hemostasis testing the development of chromogenic substrates provides an alternative to the traditional methods based on the detection of forming clots. The new technology has often replaced the clotting tests, especially in the area of single clotting factor and inhibitor assay, less frequently for global screening tests. We report studies of the validity and clinical application of two reagents for activated partial thromboplastin time (APTT) testing with chromogenic substrates in comparison with the conventional clotting method. Congenital deficiencies of the intrinsic coagulation pathway, other than hypo- and dysfibrinogenemia detected by chromogenic APTT, agreed with those detected by the clotting APTT. The results with the two methods for plasma under heparin treatment suggest a lesser responsiveness of the chromogenic methods to heparinization. The chromogenic methods demonstrated the presence of the lupus anticoagulant in the majority of tested samples of known lupus subjects, but with a lower responsiveness than the clotting method. In conclusion, we found chromogenic APTT suitable for hemostasis testing because it generally gives the same information as the conventional clotting method with the exception of heparin monitoring and lupus anticoagulant detection, where an improved sensitivity would be desirable.

KW - Activated partial thromboplastin time

KW - Chromogenic substrates

KW - Hemostasis screening tests

UR - http://www.scopus.com/inward/record.url?scp=51849183734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51849183734&partnerID=8YFLogxK

U2 - 10.1007/BF02871825

DO - 10.1007/BF02871825

M3 - Article

VL - 19

SP - 355

EP - 358

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 1

ER -